| Ytd | 96.44% | |
| 1y | 75.67% |
| Open | Prev Close | 54.65 | Low | High | Mkt Cap | 4.50B | |||
| Vol | 0.00 | Avg Vol | 2.56M | EPS | -3.75 | P/E | -14.57 | Forward P/E | -13.62 |
| Beta | -0.40 | Short Ratio | 2.33 | Inst. Own | 112.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 53.06 | 200-d Avg | 48.19 | 1yr Est | 56.50 |
AKRO News
NextCure, Inc. (NASDAQ:NXTC) ("NextCure") and Avere Therapeutics, Inc. ("Avere"), a
Bourgeon Capital Management LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDA
Corient Private Wealth LLC acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ: AKRO)
Alkeon Capital Management LLC increased its holdings in Akero Therapeutics, Inc. (NASDAQ: AKRO) by 1
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeu
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,
PHILADELPHIA , Nov. 12, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Ther
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 9
PHILADELPHIA , Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Thera
PHILADELPHIA , Oct. 29, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Thera
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde &
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, ma
Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase
Major U.S. equities indexes pulled back Thursday after the S&P 500 and Nasdaq set fresh all-time hig
MILWAUKEE , Oct. 9, 2025 /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for po
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to a
Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the ph
During Monday's trading, 1214 companies set new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.